by sfrazee | Oct 26, 2022
This paper assesses the value of take-home Alzheimer’s dementia (AD) treatments over physician-administered ones. We find that shifting from a physician-administered treatment to a home-based one in the US would generate a value of $4.67 billion to $25.51 billion...